Eptinezumab for Migraine Prevention in Patients 50 Years or Older: A Subgroup Analysis of PROMISE-1 and PROMISE-2

被引：0
|
作者：
Martin, V. [1 ]
Tassorelli, C. [2 ]
Ettrup, A. [3 ]
Hirman, J. [4 ]
Cady, R. [5 ]
机构：
[1] UC Headache & Facial Pain Ctr, Cincinnati, OH USA
[2] IRCCS C Mondino Fdn, Pavia, Italy
[3] H Lundbeck & Co AS, Copenhagen, Denmark
[4] Pacific Northwest Stat Consulting Inc, Woodinville, WA USA
[5] Lundbeck La Jolla Res Ctr, San Diego, CA USA
来源：
CEPHALALGIA | 2021年 / 41卷 / 1_SUPPL期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P0289
引用
收藏
页码：157 / 157
页数：1
相关论文
共 50 条
  • [41] A Phase 3 Study to Evaluate Eptinezumab for the Preventive Treatment of Chronic Migraine: Results of the PROMISE-2 (PRevention of Migraine via Intravenous Eptinezumab Safety and Efficacy-2) Trial
    Lipton, R. B.
    Saper, J.
    Ashina, M.
    Biondi, D.
    Bhattacharya, S.
    Hirman, J.
    Schaeffler, B.
    Cady, R.
    HEADACHE, 2018, 58 : 80 - 80
  • [42] Eptinezumab in episodic migraine: A randomized, double-blind, placebo-controlled study (PROMISE-1)
    Ashina, Messoud
    Saper, Joel
    Cady, Roger
    Schaeffler, Barbara A.
    Biondi, David M.
    Hirman, Joe
    Pederson, Susan
    Allan, Brent
    Smith, Jeff
    CEPHALALGIA, 2020, 40 (03) : 241 - 254
  • [43] Efficacy and Safety of Eptinezumab in Patients With Chronic Migraine PROMISE-2 (vol 94, pg e1365, 2020)
    Lipton
    NEUROLOGY, 2023, 101 (06)
  • [44] Eptinezumab for the Prevention of Episodic Migraine: Sustained Effect Through 1 Year of Treatment in the PROMISE-1 Study (vol 42, pg 2254, 2020)
    Smith, Timothy R.
    Janelidze, Marina
    Chakhava, George
    Cady, Roger
    Hirman, Joe
    Allan, Brent
    Pederson, Susan
    Smith, Jeff
    Schaeffler, Barbara
    CLINICAL THERAPEUTICS, 2021, 43 (04) : 791 - 791
  • [45] Quantity changes in acute headache medication use among patients with chronic migraine treated with eptinezumab: subanalysis of the PROMISE-2 study
    Cowan, Robert P.
    Marmura, Michael J.
    Diener, Hans-Christoph
    Starling, Amaal J.
    Schim, Jack
    Hirman, Joe
    Brevig, Thomas
    Cady, Roger
    JOURNAL OF HEADACHE AND PAIN, 2022, 23 (01):
  • [46] Eptinezumab Infusion Associated with Meaningful Reductions in Daily Migraine Activity on Day 1 and Over Weeks 1 Through 4 in Patients with Frequent Episodic Migraine: Results of the PROMISE-1 (PRevention Of Migraine via Intravenous eptinezumab Safety and Efficacy 1) Trial
    Cady, Roger
    Smith, Timothy
    Biondi, David
    Berman, Gary
    Freeman, Marshall
    Hirman, Joe
    Kassel, Eric
    CEPHALALGIA, 2017, 37 : 341 - 342
  • [47] Quantity changes in acute headache medication use among patients with chronic migraine treated with eptinezumab: subanalysis of the PROMISE-2 study
    Robert P. Cowan
    Michael J. Marmura
    Hans-Christoph Diener
    Amaal J. Starling
    Jack Schim
    Joe Hirman
    Thomas Brevig
    Roger Cady
    The Journal of Headache and Pain, 2022, 23
  • [48] Patient-Identified Most Bothersome Symptom in Patients With Chronic Migraine: An Analysis of PROMISE-2
    Lipton, R. B.
    Dodick, D. W.
    Ailani, J.
    Winner, P. K.
    Hindiyeh, N. A.
    Hirman, J.
    Snapinn, S.
    Mehta, L.
    Cady, R.
    HEADACHE, 2020, 60 : 117 - 118
  • [49] Eptinezumab Reduces the Frequency of Headaches and Migraines in Patients with Episodic or Chronic Migraine: Results from the PROMISE 1 and PROMISE 2 Trials
    Mechtler, L. L.
    Schim, J.
    Kassel, E.
    Cady, R.
    Hirman, J.
    HEADACHE, 2019, 59 : 34 - 34
  • [50] Patient-Identified Most Bothersome Symptom in Patients with Chronic Migraine: An Analysis of PROMISE-2
    Lipton, Richard B.
    Dodick, David W.
    Ailani, Jessica
    Winner, Paul
    Hindiyeh, Nada A.
    Hirman, Joe
    Snapinn, Steven
    Mehta, Lahar
    Cady, Roger
    NEUROLOGY, 2020, 94 (15)
12345